These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22908135)

  • 1. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
    Manolopoulou J; Alami Y; Petersenn S; Schopohl J; Wu Z; Strasburger CJ; Bidlingmaier M
    Clin Chem; 2012 Oct; 58(10):1446-56. PubMed ID: 22908135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegvisomant interference in GH assays results in underestimation of GH levels.
    Paisley AN; Hayden K; Ellis A; Anderson J; Wieringa G; Trainer PJ
    Eur J Endocrinol; 2007 Mar; 156(3):315-9. PubMed ID: 17322491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant, specific determination of growth hormone and pegvisomant in human serum.
    Ørskov H; Frystyk J; Nielsen C; Hansen AT; Weeke J; Jørgensen JO
    Growth Horm IGF Res; 2007 Oct; 17(5):431-4. PubMed ID: 17574889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay.
    Dias ML; Vieira JG; Abucham J
    Growth Horm IGF Res; 2013; 23(1-2):13-8. PubMed ID: 23206731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple, rapid immunometric assay for determination of functional and growth hormone-occupied growth hormone-binding protein in human serum.
    Fisker S; Frystyk J; Skriver L; Vestbo E; Ho KK; Orskov H
    Eur J Clin Invest; 1996 Sep; 26(9):779-85. PubMed ID: 8889440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant.
    Lüdecke DK; Crock PA; Bidlingmaier M; Schuppert F
    Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):509-12. PubMed ID: 23765756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 22-kD growth hormone exclusion assay: a new approach to measurement of non-22-kD growth hormone isoforms in human blood.
    Boguszewski CL; Hynsjö L; Johannsson G; Bengtsson BA; Carlsson LM
    Eur J Endocrinol; 1996 Nov; 135(5):573-82. PubMed ID: 8980160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of pegvisomant on serum ghrelin and leptin levels in acromegalic patients.
    Roemmler J; Otto B; Arafat AM; Bidlingmaier M; Schopohl J
    Eur J Endocrinol; 2010 Nov; 163(5):727-34. PubMed ID: 20699383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problems with GH assays and strategies toward standardization.
    Bidlingmaier M
    Eur J Endocrinol; 2008 Dec; 159 Suppl 1():S41-4. PubMed ID: 18819944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
    Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
    Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly.
    Madsen M; Fisker S; Feldt-Rasmussen U; Andreassen M; Kristensen LØ; Ørskov H; Jørgensen JO
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):92-100. PubMed ID: 23650996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interassay differences in growth hormone measurement in acromegaly.
    Barth JH; Smith JH; Clarkson P
    Ann Clin Biochem; 1997 Mar; 34 ( Pt 2)():156-9. PubMed ID: 9133248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.